newsfilter
← Latest News
GlobeNewswire·

Mersana Therapeutics Provides Business Update and Announces Third Quarter 2025 Financial Results

Day One Biopharmaceuticals, Inc. to Acquire Mersana Therapeutics, Inc.Agreement provides for upfront consideration of $25.00 per share in cash, plus potential contingent value rights cash payments of up to an aggregate